A 2026 QNova LifeSciences Report

Written by:
Jose Madrid, MHA, MBA and
Janice Cattano, RN, MSN

On February 2, 2026, the US Food and Drug Administration’s (FDA) medical device Quality Management System Regulation (QMSR) went into effect, replacing the Quality Management System (QMS). The revision incorporates by reference ISO 13485:2016 and ISO 9000:2015 Clause 3. The change reflects the FDA’s effort to better align the US Quality System requirements with global standards.

While the structure of the regulation has changed, the FDA’s expectations for manufacturers have not meaningfully softened. Companies remain fully responsible for operating an effective quality system and for demonstrating compliance with QMSR during the FDA’s inspections. For leadership teams, the most important question is not whether QMSR applies, but whether the organization understands how the FDA will evaluate the quality system under this new framework.

What is QMSR and why the FDA changed it

Historically, 21 CFR Part 820 functioned as the FDA’s quality system regulation for medical devices. Over time, many companies also implemented ISO 13485 to support international market access, resulting in parallel systems that were similar but not fully aligned.

The QMSR was the FDA’s response to this duplication. By incorporating ISO 13485:2016 and ISO 9000:2015 Clause 3 into Part 820, the FDA created a regulatory framework intended to reduce redundancy while maintaining its statutory authority in the US. The ISO 13485 now provides the core operational requirements, while Part 820 establishes scope, definitions, and the FDA’s specific additions.

What changed on February 2, 2026

Under QMSR, only two subparts of Part 820 remain active: Subpart A – General Provisions and Subpart B – Supplemental Provisions. The remaining subparts (C-O) that previously detailed quality system elements are now reserved, with manufacturers directed to ISO 13485 for those requirements.

In practice, this means that areas such as quality system documentation, management responsibility, resource management, product realization, and measurement and improvement are now primarily governed by ISO 13485. The FDA continues to expect these processes to be defined, implemented, and supported by evidence.

What did not change

Inspectors will continue to evaluate whether quality systems are effective in practice, not simply whether procedures exist. Training records, complaint files, change histories, and management oversight remain central to inspection outcomes.

The FDA also explicitly states that failure to comply with QMSR renders a device adulterated under the Federal Food, Drug, and Cosmetic Act. The regulatory consequences of noncompliance are therefore the same as under the prior Quality System framework.

For leadership teams, this reinforces an important point: QMSR is not a deregulatory shift. It is a structural and organizational change.

The FDA supplemental provisions: where attention is needed

While ISO 13485 forms the foundation of QMSR, the FDA included supplemental provisions where additional specificity was considered necessary. Two areas are particularly relevant from an executive risk perspective.

The first is control of records, including complaint and service records. The FDA expects clear decision-making around complaint evaluation, investigation, and documentation, even when complaint volumes are low or products are early in their lifecycle.

The second is labeling and packaging controls. The FDA added requirements to ensure label accuracy prior to release, reflecting long-standing inspection concerns related to uncontrolled labeling changes and inadequate review processes.

These areas frequently surface during inspections, not because of intent, but because ownership and execution are unclear.

Lastly, terms and definitions have changed, and the Quality System and Quality Manual must be updated to reflect these changes.

ISO alignment does not eliminate the FDA’s oversight

The QMSR has led some organizations to assume that ISO 13485 certification alone ensures compliance with the FDA. While ISO alignment reduces some duplication, the FDA retains authority over definitions, enforcement, and inspection outcomes. Where ISO interpretations and the FDA’s expectations diverge, the FDA’s position prevails. Therefore, a certificate of conformance to ISO 13485 will not exempt a manufacturer from an FDA audit.

From a leadership standpoint, ISO certification signals that a quality system exists and is externally audited. Readiness for the FDA depends on whether that system is implemented in a way that meets US regulatory expectations and can be clearly demonstrated during an inspection.

A practical leadership perspective on QMSR readiness

The QMSR does not necessarily require rebuilding a quality system from the ground up, if the current system incorporates both Part 820 and ISO 13485.

Important changes in the QMSR relate to terminology and definitions. Additionally, the FDA now has the authority to inspect management reviews, quality audits and supplier audit reports. The FDA has implemented a new inspection process to align with the QMSR requirements.

How QNova LifeSciences supports organizations navigating QMSR

QNova LifeSciences supports medical device organizations by helping leadership teams and internal stakeholders understand QMSR requirements and develop the internal capability to operate a compliant quality system. QNova does not manage quality systems on behalf of companies. Instead, support is centered on auditing the current Quality System and providing an assessment on how to be compliant with QMSR, providing the documents needed to be compliant with QMSR, training, and structured regulatory guidance so organizations can execute and sustain their systems internally. Additionally, QNova can conduct the required annual internal audit of the organization’s Quality System, can prepare companies for an FDA audit, and can provide on-site support during an FDA audit. For companies that are getting ready for initial product commercialization, QNova can provide a QMSR system that is compliant with both 21 CFR 820 and ISO 13485.

Closing perspective: Where this leaves medical device companies

The QMSR represents a shift toward global alignment, not a fundamental change in the FDA’s expectations. What matters most has not changed: quality systems must be understood, owned, and consistently executed. If your quality system has not been updated to reflect the requirements of QMSR, it is critical to implement the changes now.

Contact us at: info@qnovals.com or contact Jim Sergi at 800-229-5764 to learn more.